Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Abstract Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Формат: Artigo
Язык:Inglês
Опубликовано: Wiley 2019-12-01
Серии:Clinical and Translational Medicine
Предметы:
Glioblastoma
Recurrent glioblastoma
Glioblastoma stem cells
High-throughput drug screening
Drug sensitivity and resistance testing
Individualized medicine
Online-ссылка:http://link.springer.com/article/10.1186/s40169-019-0253-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы